StonvexLoading…
StonvexStonvexStonvexCore line items from ZYME's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $105.97M | $76.30M | $76.01M | $412.48M |
Operating Income | $-92.55M | $-137.11M | $-138.05M | $130.53M |
Net Income | $-81.13M | $-122.69M | $-118.67M | $124.34M |
EPS (Diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 |
Total Assets | $346.53M | $463.09M | $580.88M | $648.73M |
Total Liabilities | $78.03M | $124.32M | $116.07M | $155.77M |
Cash & Equivalents | $41.16M | $66.10M | $157.56M | $400.91M |
Free Cash Flow OCF − CapEx | $-34.53M | $-112.05M | $-120.80M | $135.96M |
Shares Outstanding | 74.64M | 68.96M | 70.12M | 63.06M |